CD8A and familial pancreatic carcinoma: In a model of pancreatic cancer, treatment with GB1275 was sufficient to reduce tumour infiltration of CD11b+ TAMs, and increase the influx of activated CD103+ DCs and CD8+ T cells, and combined treatment with GB1275 and an anti-PD-1 blocking antibody gave a significant survival advantage compared with either treatment on its own [36].